RxDoctor Payments Data

John Hahn, MD

Gastroenterology · Bayonne, NJNPI 1538272091

Payments from drug & device makers

$3,483in general payments, 2019–2025

Across 89 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Davol Inc.$2K
  • AbbVie$284
  • Ardelyx, Inc.$262
  • Johnson & Johnson$248
  • Gilead$218
  • Takeda Pharmaceuticals U.S.A., Inc.$206
  • plus $761 from 10 others

What the payments were for

  • Travel & lodging$1,26236%
  • Food & beverage$2,22164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,483 in reported general payments places this provider in the 55th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$76,126
Medicare patients
324
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid28$265,971
LinzessLinaclotide77$84,379
Mesalamine77$45,225
Dexlansoprazole DrDexlansoprazole55$16,699
Ursodiol22$7,248
Omeprazole423$6,482
DexilantDexlansoprazole15$6,406
Balsalazide Disodium16$4,359
CholestyramineCholestyramine (With Sugar)23$3,228
Mercaptopurine21$2,977
Esomeprazole Magnesium58$2,199
Lansoprazole25$1,220
Pantoprazole Sodium70$1,031
Hydrocortisone25$260
Ondansetron Hcl12$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$112$265,97128 claims
AbbVieLinzess$284$84,37977 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$206$6,40615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →